Payment overview · 2025
General Payments
$306.55
20 reported records · 7 companies
Healthcare provider profile · identity verified
David H Mosley, MD
Allopathic & Osteopathic Physicians|Family Medicine · CAMDEN, AR · NPI 1619943271
Verified facts
What the public records show
CMS Open Payments records show David H Mosley, MD received $306.55 in general payments during 2025 across 20 reported records.
ABBVIE INC. accounted for 48.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 240 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $148.58 | 48.5% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $55.63 | 18.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.82 | 10.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $23.21 | 7.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.86 | 6.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.92 | 4.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.53 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $306.55 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $115.89 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $115.89 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $41.42 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $32.69 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $30.82 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $30.82 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.92 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.53 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 239 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 240 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
85 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
240 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
239 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
28 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1299 | 370 |
| Amlodipine Besylate | Amlodipine Besylate | 749 | 215 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 734 | 98 |
| Gabapentin | Gabapentin | 595 | 130 |
| Potassium Chloride | Potassium Chloride | 562 | 137 |
| Pantoprazole Sodium | Pantoprazole Sodium | 502 | 132 |
| Levothyroxine Sodium | Levothyroxine Sodium | 452 | 109 |
| Losartan Potassium | Losartan Potassium | 408 | 121 |
| Omeprazole | Omeprazole | 389 | 99 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 364 | 103 |
| Metoprolol Succinate | Metoprolol Succinate | 336 | 80 |
| Metformin Hcl | Metformin Hcl | 323 | 85 |
| Furosemide | Furosemide | 319 | 96 |
| Sertraline Hcl | Sertraline Hcl | 313 | 70 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 299 | 99 |
| Metoprolol Tartrate | Metoprolol Tartrate | 263 | 70 |
| Tizanidine Hcl | Tizanidine Hcl | 262 | 73 |
| Ozempic | Semaglutide | 240 | 36 |
| Eliquis | Apixaban | 239 | 41 |
| Carvedilol | Carvedilol | 237 | 61 |
| Fluticasone Propionate | Fluticasone Propionate | 223 | 89 |
| Alprazolam | Alprazolam | 217 | 38 |
| Glipizide Er | Glipizide | 200 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 200 | 50 |
| Allopurinol | Allopurinol | 197 | 54 |
| Meloxicam | Meloxicam | 194 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 194 | 49 |
| Tramadol Hcl | Tramadol Hcl | 191 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 190 | 54 |
| Lorazepam | Lorazepam | 184 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 180 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 177 | 53 |
| Famotidine | Famotidine | 173 | 52 |
| Trazodone Hcl | Trazodone Hcl | 173 | 33 |
| Metformin Hcl Er | Metformin Hcl | 167 | 49 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 163 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 160 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 158 | 40 |
| Alendronate Sodium | Alendronate Sodium | 156 | 29 |
| Pregabalin | Pregabalin | 151 | 33 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 146 | 35 |
| Lisinopril | Lisinopril | 142 | 40 |
| Mirtazapine | Mirtazapine | 139 | 33 |
| Baclofen | Baclofen | 131 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 131 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 124 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 122 | 33 |
| Prednisone | Prednisone | 118 | 65 |
| Buspirone Hcl | Buspirone Hcl | 116 | 23 |
| Glimepiride | Glimepiride | 116 | 35 |
| Clonazepam | Clonazepam | 114 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 113 | 32 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 110 | 72 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 109 | 22 |
| Donepezil Hcl | Donepezil Hcl | 103 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 100 | 43 |
| Meclizine Hcl | Meclizine Hcl | 100 | 31 |
| Nifedipine Er | Nifedipine | 99 | 24 |
| Simvastatin | Simvastatin | 95 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 91 | 81 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 91 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 90 | 18 |
| Jardiance | Empagliflozin | 85 | 15 |
| Glipizide | Glipizide | 82 | 25 |
| Symbicort | Budesonide/Formoterol Fumarate | 82 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 81 | 18 |
| Naproxen | Naproxen | 78 | 25 |
| Warfarin Sodium | Warfarin Sodium | 77 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 75 | 18 |
| Ibuprofen | Ibuprofen | 74 | 21 |
| Mupirocin | Mupirocin | 73 | 53 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 19 |
| Methylprednisolone | Methylprednisolone | 72 | 64 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 70 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 70 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 70 | suppressed |
| Xarelto | Rivaroxaban | 68 | suppressed |
| Spironolactone | Spironolactone | 65 | 16 |
| Montelukast Sodium | Montelukast Sodium | 63 | 12 |
| Estradiol | Estradiol | 61 | 21 |
| Celecoxib | Celecoxib | 60 | 25 |
| Clonidine Hcl | Clonidine Hcl | 60 | 20 |
| Levetiracetam | Levetiracetam | 60 | 13 |
| Valsartan | Valsartan | 60 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 59 | 25 |
| Finasteride | Finasteride | 57 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 57 | 36 |
| Pioglitazone Hcl | Pioglitazone Hcl | 56 | 16 |
| Primidone | Primidone | 52 | 12 |
| Verapamil Er | Verapamil Hcl | 50 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 49 | 12 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 47 | 12 |
| Clindamycin Hcl | Clindamycin Hcl | 45 | 41 |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 45 | 13 |
| Memantine Hcl | Memantine Hcl | 44 | suppressed |
| Enulose | Lactulose | 43 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 41 | 12 |
| Ezetimibe | Ezetimibe | 41 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 39 | 12 |
| Enalapril Maleate | Enalapril Maleate | 38 | 12 |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 16 |
| Acyclovir | Acyclovir | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | 16 |
| Fluconazole | Fluconazole | 32 | 23 |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Methocarbamol | Methocarbamol | 32 | 13 |
| Promethazine Hcl | Promethazine Hcl | 32 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 31 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 31 | 14 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 31 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 30 | suppressed |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 29 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 28 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 28 |
| Cilostazol | Cilostazol | 27 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Latanoprost | Latanoprost | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 23 |
| Azelastine Hcl | Azelastine Hcl | 24 | 16 |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Nystatin | Nystatin | 23 | 13 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Zaleplon | Zaleplon | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Cefdinir | Cefdinir | 21 | 19 |
| Fentanyl | Fentanyl | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 20 |
| Droplet Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Phenobarbital | Phenobarbital | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | 11 |
| Topiramate | Topiramate | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Etodolac | Etodolac | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 13 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 15 |
| Torsemide | Torsemide | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 14 | suppressed |
| Indapamide | Indapamide | 14 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 13 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Sulindac | Sulindac | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $306.55 · 20 records | ABBVIE INC. | CAPLYTA, Dexcom G6 Transmitter, ELIQUIS, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error